regulates the expression and enzyme activity of 11␤-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 292: E1213-E1222, 2007. First published December 26, 2006; doi:10.1152/ajpendo.00340.2006.-A clinically employed antihyperlipidemic drug, bezafibrate, has been characterized as a PPAR(␣, -␥, and -␦) pan-agonist in vitro. Recent extended trials have highlighted its antidiabetic properties in humans. However, the underlying molecular mechanism is not fully elucidated. The present study was designed to explore potential regulatory mechanisms of intracellular glucocorticoid reactivating enzyme, 11␤-HSD1 and anti-diabetic hormone, adiponectin by bezafibrate in murine adipose tissue, and cultured adipocytes. Treatment of db/db mice with bezafibrate significantly ameliorated hyperglycemia and insulin resistance, accompanied by a marked reduction of triglyceride and nonesterified fatty acids. Despite equipotent in lipid-lowering effects, another fibrate, fenofibrate, did not show such beneficial effects on glycemic control. Treatment of bezafibrate caused a marked decrease in the mRNA level of 11␤-HSD1 preferentially in adipose tissue of db/db mice (Ϫ47%, P Ͻ 0.05), concomitant with a significant increase in plasma adiponectin level (ϩ37%, P Ͻ 0.01). Notably, treatment of bezafibrate caused a marked decrease in the mRNA level (Ϫ34%, P Ͻ 0.01) and enzyme activity (Ϫ32%, P Ͻ 0.01) of 11␤-HSD1, whereas the treatment substantially augmented the expression (ϩ71%, P Ͻ 0.01) and secretion (ϩ27%, P Ͻ 0.01) of adiponectin in 3T3-L1 adipocytes. Knockdown of 11␤-HSD1 by siRNA confirmed that 11␤-HSD1 acts as a distinct oxoreductase in adipocytes and validated the enzyme activity assays in the present study. Effects of bezafibrate on regulation of 11␤-HSD1 and adiponectin in murine adipocytes were comparable with those in thiazolidinediones. This is the first demonstration that bezafibrate directly regulates 11␤-HSD1 and adiponectin in murine adipocytes, both of which may contribute to metabolicallybeneficial effects by bezafibrate. metabolic syndrome; adiponectin FAMILY GENES of peroxisome proliferator-activated receptors (PPARs) are profoundly relevant to fuel homeostasis (14, 41). Agonists for PPAR␣ and PPAR␥ have been widely used for the treatment of dyslipidemia and type 2 diabetes (46). Recent research progress (3) has highlighted the potential usefulness of PPAR␣/␥ dual agonists or PPAR(␣, -␥, and -␦) pan-agonists for metabolic diseases. However, some of these compounds are reported to cause adverse effects, including carcinogenesis, edema, hepatotoxicity, and increase in body weight in rodent experiments (45). Bezafibrate has been widely used for the treatment of dyslipidemia in human clinics (11). Recent in vitro experiments have shown that bezafibrate serves as a pan-agonist for PPAR␣, -␥, and -␦ (9, 48). Furthermore, recent extended clinical trials (15, 43) have highlighted its antidiabetic properties. However, the underlying mechanism is not fully clarified. To explore unidentified mechanisms whereby bezafibrate ameliorates metabolic derangement, using genetically obese diabetic BKS.Cg-ϩLepr db /ϩLept db (db/db) mice, which represent a cluster of detrimental metabolic sequelae such as morbid obesity, diabetes, dyslipidemia, and liver steatosis (39), we examined metabolic response to bezafibrate.
FAMILY GENES of peroxisome proliferator-activated receptors (PPARs) are profoundly relevant to fuel homeostasis (14, 41) . Agonists for PPAR␣ and PPAR␥ have been widely used for the treatment of dyslipidemia and type 2 diabetes (46) . Recent research progress (3) has highlighted the potential usefulness of PPAR␣/␥ dual agonists or PPAR(␣, -␥, and -␦) pan-agonists for metabolic diseases. However, some of these compounds are reported to cause adverse effects, including carcinogenesis, edema, hepatotoxicity, and increase in body weight in rodent experiments (45) . Bezafibrate has been widely used for the treatment of dyslipidemia in human clinics (11) . Recent in vitro experiments have shown that bezafibrate serves as a pan-agonist for PPAR␣, -␥, and -␦ (9, 48) . Furthermore, recent extended clinical trials (15, 43) have highlighted its antidiabetic properties. However, the underlying mechanism is not fully clarified. To explore unidentified mechanisms whereby bezafibrate ameliorates metabolic derangement, using genetically obese diabetic BKS.Cg-ϩLepr db /ϩLept db (db/db) mice, which represent a cluster of detrimental metabolic sequelae such as morbid obesity, diabetes, dyslipidemia, and liver steatosis (39), we examined metabolic response to bezafibrate.
Intracellular glucocorticoid reactivating enzyme 11␤-hydroxysteroid dehydrogenase type 1 (11␤-HSD1) is abundantly expressed in liver, adipose tissue, skeletal muscle, and central nervous system (38) . Targeted overexpression of 11␤-HSD1 in adipose tissue in mice results in visceral fat obesity, insulin resistance, and hypertension, suggesting that increased level of adipose 11␤-HSD1 plays a critical role in metabolic derangements by providing local glucocorticoid excess within fat cells (29, 30) . On the other hand, 11␤-HSD1 knockout mice (32) , as well as adipose-specific 11␤-HSD2 overexpressors, which mimicked adipose-specific 11␤-HSD1 knockout mice (18) , are protected against the metabolic syndrome under overnutrition. Furthermore, recent studies (36, 47) in rodents suggest that local glucocorticoid excess mediated by 11␤-HSD1 in liver or skeletal muscle is also involved in the pathophysiology of the metabolic diseases.
Here, we show that bezafibrate potently decreases the mRNA level of 11␤-HSD1 (28) in adipose tissue of db/db mice. We also demonstrate for the first time that bezafibrate inhibits the expression and enzyme activity of 11␤-HSD1 in 3T3-L1 adipocytes. Our data show that bezafibrate potently increases the plasma level of antidiabetic adiponectin (26) in mice and augments substantially the expression and secretion of adiponectin in 3T3-L1 adipocytes. To our knowledge, this is the first study to demonstrate that bezafibrate potently regulates 11␤-HSD1 and adiponectin in murine fat cells.
MATERIALS AND METHODS

Materials.
Bezafibrate was obtained from Chugai Pharmaceutical (Tokyo, Japan). Fenofibrate and WY-14,643 were purchased from Sigma-Aldrich (St. Louis, MO). Pioglitazone hydrochloride (pioglitazone), fenofibric acid, an active metabolite of fenofibrate, and rosiglitazone were synthesized by Kissei Pharmaceutical (Matsumoto, Japan). WY-14,643 and fenofibric acid were used for in vitro experiments.
Animal experiments. Animal experiments in the present study were conducted in accordance with the guidelines for animal experiments of Kissei Pharmaceutical and the Animal Research Committee, Graduate School of Medicine, Kyoto University, and were approved by the Japanese Pharmacological Society. Six-week-old male BKS.Cg-mϩ/ ϩLept db /Jcl (lean) mice and their obese littermates, BKS.CgϩLepr db /ϩLept db /Jcl (db/db) mice, were purchased from Clea Japan (Tokyo, Japan). Mice were housed individually with free access to tap water and commercial pellet food (CE-2; Clea Japan) and kept at 23°C with a humidity of 55% under a 12:12-h light-dark cycle. Mice were randomly divided into groups before each experiment. Bezafibrate (100 or 300 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ), fenofibrate (300
, or vehicle (1% methylcellulose) were orally administered to db/db mice once per day at ϳ10:00 AM for 6 or 8 wk. Simultaneously, vehicle was administered to lean mice for 6 or 8 wk. Body weight and food consumption were monitored twice per week.
Measurement of metabolic parameters in plasma. Blood samples were collected from tail vein with heparinized hematocrit tube into the collection tube with 50 U aprotinin (Trasylol; Bayer Yakuhin, Osaka, Japan) when fed ad libitum at around 10:00 AM. Plasma glucose, triglyceride (TG), and nonesterified fatty acids (NEFA) were measured via commercially-available kits (Glucose CII-test, Triglyceride E-test, and NEFA C test, respectively; Wako Pure Chemical Industries, Osaka, Japan). Plasma LDL cholesterol and HDL cholesterol were measured by Cholestest LDL and Cholestest N HDL (Daiichi Pure Chemicals, Tokyo, Japan) with a biochemistry automatic analyzer (Clinical analyzer 7150; Hitachi High-Technologies, Tokyo, Japan). Plasma insulin, leptin, adiponectin, and corticosterone concentrations were determined using Insulin ELISA kit, Mouse Leptin ELISA kit (Morinaga Institute of Biological Science, Yokohama, Japan), Mouse/Rat Adiponectin ELISA Kit (Otsuka Pharmaceutical, Tokushima, Japan), and AssayMax Corticosterone ELISA kit (AssayPro, Winfield, MO), respectively.
Oral glucose tolerance test. At 4 wk after the treatments were initiated, db/db and lean mice fasted for 12 h were orally administered 2 g/kg body wt glucose (Wako Pure Chemical Industries). Blood sample was collected from tail vein at 0.5, 1, 1.5, and 2 h after glucose load. The areas under the curve (AUC) of glucose levels (0 -0.5 and 0 -1 h) were calculated to assess the status of glucose homeostasis by the linear trapezoidal equation (35) .
Intravenous insulin tolerance test. At 2 wk after the treatments were initiated, db/db and lean mice fasted for 12 h were injected 0.8 U/kg body wt insulin (Novo Nordisk Pharma, Tokyo, Japan) via the tail vein. Blood was collected from tail vein at 0.5, 1, 1.5, and 2 h after insulin injection. The AUC of glucose levels (0 -0.5 and 0 -1 h) were calculated to assess the status of insulin resistance by the equation described above.
TG and total cholesterol contents in liver. At 8 wk after the treatments were initiated, mice were anesthetized with intraperitonial injection of 20% chloral hydrate (Wako Pure Chemical Industries). Removed liver tissue was quickly weighed, and one part was homogenized and subjected to lipid extraction according to the method of Folch et al. (7) . Hepatic TG and cholesterol contents were measured using commercially available kits (TG E-test and cholesterol E-test; Wako Pure Chemical Industries).
Determination of mRNA levels. Total RNA was isolated from liver, mesenteric fat, subcutaneous fat, triceps surae muscle, and 3T3-L1 adipocytes by Isogen (Nippon Gene, Tokyo, Japan). The mRNA level corresponding to a couple of target genes was determined by real-time quantitative RT-PCR using a GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA). Primers and doubledye probes for carnitine palmitoyltransferase (CPT) I, acyl-CoA oxidase (ACO), uncoupling protein (UCP)3, and adiponectin were designed using Primer Express 2.0 (Applied Biosystems; Table 1 ). Primers and double-dye probes for 11␤-HSD1 and UCP2 were designed as described previously (1, 16) . Results were normalized to 18S ribosomal RNA concentration determined by PreDeveloped TaqMan Assay Reagents (Applied Biosystems).
Cell culture and treatment. 3T3-L1 preadipocytes (passages 3-10; American Type Culture Collection, Manassas, VA) were grown and differentiated into adipocytes, as described previously (8) . Briefly, differentiation was induced by incubating the cells in DMEM that included 10% FBS with 0.5 mmol/l IBMX, 1 mol/l dexamethazone, and 10 g/ml insulin for 2 days, followed by another 2-day incubation in DMEM that included 10% FBS with 10 g/ml insulin. The cells were further incubated in DMEM with 10% FBS for an additional 4 days to complete the adipocyte conversion. At day 8 following the initiation of differentiation, vehicle (1% DMSO), bezafibrate (1-300 mol/l), rosiglitazone (3 mol/l), pioglitazone (10 mol/l), fenofibric acid (1-300 mol/l), or WY-14,643 (1-10 mol/l) were replenished to cultured cells and coincubated from 8 to 48 h at 37°C in 5% CO 2. Suppression of 11␤-HSD1 expression by RNA interference. 11␤-HSD1 expression in 3T3-L1 differentiated adipocytes was suppressed by a small interfering RNA (siRNA) duplex oligonucleotide-targeted 11␤-HSD1 mRNA sequence. Individual siRNA duplex was designed using a siRNA Design Support System (TaKaRa Bio, Shiga, Japan). 3T3-L1 differentiated adipocytes (day 8) were transfected with the siRNA duplex (10 nmol/l; sense: 5Ј-GAAAUGGCAUAUCAUCU-GUTT-3Ј and antisense: 3Ј-TTCUUUACCGUAUAGUAGACA-5Ј) using TransIT-TKO Transfection Reagent (Mirus Bio, Madison, WI) for 48 h. Negative Control siRNA (Qiagen, Tokyo, Japan) was used as a nonsilencing control.
Measurement of 11␤-HSD1 enzyme activity. Oxoreductase enzyme activity of 11␤-HSD1 was assessed according to a previous report (5) , with slight modification. Assays for 11␤-HSD1 activity were performed by incubating intact cells with corticosteroids with appropriate tritiated tracer. In assays for oxoreductase activity, cells were incubated in serum-free DMEM containing 250 nmol/l cortisone with appropriate tritium-labeled tracer [1,2- 3 H2]cortisone (50 Ci/mmol; American Radiolabeled Chemicals, St. Louis, MO). After the incubation at 37°C for indicated time, corticosteroids were extracted using ethyl acetate, separated by thin layer chromatography (TLC) in chloroform-methanol (95:5), and quantified by autoradiography. 11␤-HSD1 oxoreductase activities were expressed as pmol product ([1,2-3 H2]cortisol) ⅐ min Ϫ1 ⅐ well Ϫ1 after correction for apparent conversion in reactions without cells.
Western blot analysis. 3T3-L1 pre-or differentiated adipocytes were coincubated with drugs or vehicle for 24 h. Proteins in cultured media (25 ng/lane) were separated by standard Laemmli's method (23) and subjected to immunoblotting. Western blot analyses were performed using anti-mouse adiponectin antibody (MAB3608; Chemicon International, Temecula, CA).
Statistical analyses. All data were expressed as means Ϯ SE. All statistical analyses were performed using SAS System Version 8.2 (SAS Institute, Cary, NC) and its interlocking movement program, Clinical Package Version 5.0. Student's t-test was performed between 1) vehicle-treated lean mice and vehicle-treated db/db mice, 2) vehicle-treated 3T3-L1 differentiated adipocytes and vehicle-treated 3T3-L1 preadipocytes, and 3) nontransfected control and nonsilencing control or siRNA transfected for RNA interference experiments. In case of multiple comparisons, one-way analysis of variance (ANOVA) followed by post hoc analysis of Dunnett's multiple comparison test was performed. Statistical analysis between vehicletreated db/db mice and other groups in oral glucose tolerance test (OGTT) and intravenous insulin tolerance test (IVITT) were performed using Student's t-test or Dunnett's multiple comparison test, followed by univariate repeated-measures ANOVA, taking pretreatment values as covariate. Differences were considered significant at P Ͻ 0.05.
RESULTS
Body weight and food consumption. Increment in body weight and food consumption in db/db mice was exaggerated compared with lean mice during the course of the experiment (P Ͻ 0.01). Both bezafibrate and fenofibrate tended to increase body weight compared with vehicle-treated db/db mice (P ϭ 0.055 by ANOVA; Table 2 ).
Liver and mesenteric fat weight. Liver and mesenteric fat weight in vehicle-treated db/db mice was significantly elevated compared with vehicle-treated lean mice (P Ͻ 0.01; Table 2 ). Treatments of both bezafibrate and fenofibrate significantly increased liver weight compared with vehicle-treated db/db mice, whereas increase in liver weight in fenofibrate treatment was exaggerated compared with that in bezafibrate treatment ( Table 2 ). It should be noted that both treatments did not significantly increase mesenteric fat weight (P ϭ 0.63 by ANOVA; Table 2 ).
Plasma lipid parameters. Plasma levels of TG, NEFA, HDL cholesterol, and LDL cholesterol in vehicle-treated db/db mice at 15 wk of age were significantly higher than those in vehicle-treated lean mice (P Ͻ 0.01; Table 2 ). Both bezafibrate and fenofibrate markedly lowered plasma TG levels to around normal range at 8 wk after the treatments were initiated (Table  2 ). In addition, both treatments significantly lowered plasma level of NEFA (Table 2) . Furthermore, both compounds significantly increased HDL cholesterol level in plasma (Table 2) . In contrast, both compounds did not alter LDL cholesterol level in plasma (Table 2) .
Hepatic TG and total cholesterol contents. Hepatic TG content in vehicle-treated db/db mice at 15 wk of age was significantly higher than that in vehicle-treated lean mice (P Ͻ . NEFA, nonesterified fatty acids. ##P Ͻ 0.01 vs. vehicle-treated db/db mice (Student's t-test). *P Ͻ 0.05; **P Ͻ 0.01 vs. vehicle-treated db/db mice (1 way ANOVA followed by Dunnett's multiple comparison test). 0.01; Table 2 ). Bezafibrate and fenofibrate significantly reduced hepatic TG and total cholesterol contents compared with vehicle-treated db/db mice ( Table 2) .
Plasma glucose and insulin levels. Plasma glucose levels in vehicle-treated db/db mice at 15 wk of age were significantly higher than those in vehicle-treated lean mice (P Ͻ 0.01; Fig.  1A ). Bezafibrate significantly reduced plasma glucose levels at 8 wk after the treatments were initiated. In contrast, fenofibrate did not show beneficial effects on plasma glucose levels (Fig.  1A) . Plasma insulin levels in vehicle-treated db/db mice at 15 wk of age tended to be higher than those in vehicle-treated lean mice (P ϭ 0.12; Fig. 1B ). Both bezafibrate and fenofibrate showed a trend toward reducing plasma insulin levels at 8 wk after the treatments were initiated (P ϭ 0.78 by ANOVA; Fig.  1B) .
OGTT and IVITT. To further assess the potential impact of drug administration on glucose tolerance and insulin sensitivity, OGTT and IVITT were performed in db/db mice and lean mice. At 4 wk after the treatments were initiated, bezafibrate, pioglitazone, and rosiglitazone significantly lowered plasma glucose levels compared with vehicle-treated db/db mice, but not fenofibrate (bezafibrate: 117 Ϯ 21 mg/dl, P ϭ 0.0004; fenofibrate: 197 Ϯ 23 mg/dl, P ϭ 0.24; pioglitazone: 143 Ϯ 21 mg/dl, P ϭ 0.006; rosiglitazone: 147 Ϯ 27 mg/dl, P ϭ 0.007 vs. vehicle-treated db/db mice; Fig. 2A) . Glucose levels at each time point were significantly elevated in vehicle-treated db/db mice compared with vehicle-treated lean mice ( Fig. 2A) . AUC 0 -0.5 h and AUC 0 -1 h in vehicle-treated db/db mice were significantly higher than those in vehicle-treated lean mice (Table 3) . Bezafibrate, pioglitazone, rosiglitazone and fenofibrate significantly reduced AUC 0 -0.5 h and AUC 0 -1 h (Table 3) .
Reduction of AUC 0 -0.5 h and AUC 0 -1 h in bezafibrate was exaggerated compared with fenofibrate.
At 2 wk after the treatments were initiated, bezafibrate and rosiglitazone significantly lowered plasma glucose levels compared with vehicle-treated db/db mice, but not pioglitazone and fenofibrate (bezafibrate: 197 Ϯ 22 mg/dl, P ϭ 0.005; fenofibrate: 253 Ϯ 21 mg/dl, P ϭ 0.20; pioglitazone: 258 Ϯ 35 mg/dl, P ϭ 0.31; rosiglitazone: 216 Ϯ 28 mg/dl, P ϭ 0.021 vs. vehicle-treated db/db mice; Fig. 2B ). At 0.5 h after the insulin injection in IVITT, bezafibrate, pioglitazone, and rosiglitazone significantly reduced plasma glucose levels (P Ͻ 0.05). On the other hand, glucose-lowering effects in fenofibrate-treated mice were marginal (P ϭ 0.29; Fig. 2B ). AUC 0 -0.5 h and AUC 0 -1 h in vehicle-treated db/db mice were significantly higher than those in vehicle-treated lean mice (Table 3) . Bezafibrate, pioglitazone, and rosiglitazone significantly reduced the value of AUC 0 -0.5 h , and reduction of AUC 0 -1 h in bezafibrate was equipotent to rosiglitazone (Table 3 ). In contrast, fenofibrate represented no significant effects on AUCs.
Plasma leptin, adiponectin, and corticosterone levels. Plasma leptin levels in vehicle-treated db/db mice were markedly elevated compared with vehicle-treated lean mice (P Ͻ 0.01). Treatments of bezafibrate and fenofibrate did not change plasma leptin levels significantly in db/db mice (P ϭ 0.08 by ANOVA), whereas pioglitazone significantly decreased the levels (Fig. 1C) .
Plasma adiponectin levels in vehicle-treated db/db mice were significantly lower than those in vehicle-treated lean mice (P Ͻ 0.01; Fig. 1D ). Treatments of bezafibrate, pioglitazone, and rosiglitazone caused a significant rise in plasma adiponec- 
), or vehicle (Vehi) and vehicle-treated lean mice (n ϭ 7-8 in each). Each column shows plasma glucose, insulin, and leptin levels at 8 wk and adiponectin levels in mice at 6 wk after the treatments were initiated. Data are presented as means Ϯ SE. *P Ͻ 0.05; **P Ͻ 0.01 vs. vehicle-treated db/db mice; ##P Ͻ 0.01 vs. vehicle-treated db/db mice. tin levels. Conversely, fenofibrate rather decreased the levels compared with vehicle-treated db/db mice (Fig. 1D) .
Plasma corticosterone level in vehicle-treated db/db mice (133.7 Ϯ 21.3 ng/ml) was markedly elevated compared with vehicle-treated lean mice (37.4 Ϯ 14.5 ng/ml, P Ͻ 0.01). Treatments of bezafibrate, fenofibrate, and pioglitazone did not significantly change plasma corticosterone levels in db/db mice (bezafibrate: 122.7 Ϯ 14.2 ng/ml; fenofibrate: 121.2 Ϯ 8.5 ng/ml; pioglitazone: 132.6 Ϯ 14.7 ng/ml).
Expression of genes related to fuel metabolism in liver.
It is well known (2) that the activation of PPAR␣ induces mRNA expression of a series of genes involved in lipid handling and fatty acid ␤-oxidation. In liver, there were no significant differences in mRNA level of CPT I, ACO, UCP2, or UCP3 between vehicle-treated db/db and vehicle-treated lean mice (Table 4) . On the other hand, both bezafibrate and fenofibrate markedly increased the levels for CPT I (P ϭ 0.30 by ANOVA), ACO, UCP2, and UCP3 (bezafibrate, P ϭ 0.23) compared with vehicle-treated db/db mice ( Table 4) .
Expression of 11␤-HSD1 mRNA. In liver, triceps surae muscle, mesenteric fat, and subcutaneous fat, 11␤-HSD1 mRNA levels in vehicle-treated db/db mice were significantly higher than those in vehicle-treated lean mice (Fig. 3) . In liver, bezafibrate, fenofibrate, and pioglitazone significantly decreased the 11␤-HSD1 mRNA levels (Fig. 3A) . In triceps surae muscle, bezafibrate and fenofibrate also showed a trend toward a decrease in the 11␤-HSD1 mRNA levels, but these effects were marginal (Fig. 3A) .
Of note, in mesenteric fat, bezafibrate and pioglitazone substantially decreased the 11␤-HSD1 expression levels, whereas fenofibrate did not affect the levels (Fig. 3B) . In subcutaneous fat, bezafibrate also showed a trend toward lower levels of 11␤-HSD1, which were comparable to those in pioglitazone. In contrast, fenofibrate had no effects (Fig. 3B) .
mRNA expression levels and enzyme activity of 11␤-HSD1 in bezafibrate-treated 3T3-L1 adipocytes. The mRNA levels of 11␤-HSD1 in 3T3-L1 differentiated adipocytes were apparently higher than those in vehicle-treated 3T3-L1 preadipocytes. Importantly, bezafibrate, rosiglitazone, and pioglitazone markedly reduced the 11␤-HSD1 mRNA levels in 3T3-L1 differentiated adipocytes at 48 h after the treatments. In contrast, fenofibrate and WY-14,643 had no effect on 11␤-HSD1 mRNA levels (Fig. 4A) .
To further explore the impact on enzyme activity of 11␤-HSD1, cells were incubated with tritium-labeled cortisone. Assay for 11␤-HSD1 activity clearly showed that 11␤-HSD1 acted as distinct oxoreductase in 3T3-L1 differentiated adipocytes (Vehi; Fig. 4B ). Bezafibrate, rosiglitazone, and pioglitazone considerably inhibited cortisone-to-cortisol conversion for 48-h treatment (Fig. 4B) . Actually, bezafibrate, rosiglitazone, and pioglitazone markedly reduced 11␤-HSD1 oxoreductase ac- (Fig. 4C) .
Suppression of 11␤-HSD1 expression and enzyme activity by transfection with a siRNA duplex.
To validate the enzyme activity assay in the present study, 3T3-L1 differentiated adipocytes were transfected with siRNA duplex targeted to 11␤-HSD1 mRNA sequence. The mRNA levels of 11␤-HSD1 were markedly reduced by transfection of siRNA duplex (P Ͻ 0.01; Fig. 4D) . Consequently, the enzyme activity of 11␤-HSD1 was also reduced (P Ͻ 0.05; Fig. 4E ).
Adiponectin level in cultured media of bezafibrate-treated 3T3-L1 adipocytes. Adiponectin levels in cultured media of 3T3-L1 adipocytes were determined by Western blot analysis. Adiponectin protein was detected as a single band at ϳ35 kDa (Fig. 5A) . Adiponectin protein from vehicle-treated 3T3-L1 preadipocytes was under detectable range. Of note, bezafibrate and rosiglitazone markedly increased adiponectin level in cultured media. In contrast, adiponectin levels in media of cells treated with fenofibric acid did not increase at all (Fig. 5B) .
The mRNA levels of adiponectin in 3T3-L1 adipocytes were determined at the point of 8, 16, and 24 h after the each treatment. Bezafibrate and rosiglitazone increased mRNA levels of adiponectin from 8 to 24 h in a time-dependent manner, with significant increases at 16 and 24 h (Fig. 5C) . Consequently, at 24 h after the treatment, bezafibrate, rosiglitazone, and pioglitazone significantly increased the adiponectin mRNA levels (Fig. 5D ).
DISCUSSION
Recent extensive clinical trials (43) provided compelling evidence that bezafibrate reduces the incidence of type 2 diabetes in patients with coronary artery diseases. To our knowledge, however, the underlying molecular mechanism of its metabolically beneficial effects has not been fully elucidated. The present study confirmed that repeated administration of bezafibrate significantly ameliorated hyperglycemia and insulin resistance in db/db mice. Nevertheless, antihyperlipidemic effects of fenofibrate were equipotent to bezafibrate (Table 2) , and improvement of glucose homeostasis by fenofibrate was marginal compared with bezafibrate. In the present study, 100 or 300 mg⅐kg Ϫ1 ⅐day Ϫ1 of bezafibrate and 300 mg⅐kg Ϫ1 ⅐day Ϫ1 of fenofibrate were administered. Because the sensitivity of PPAR␣ agonists in terms of fuel homeostasis in rodents is known to be much lower than in humans, higher doses have been commonly used for rodent experiments (12, 22, 49) . Administered doses of compounds were decided mainly on the basis of their plasma TG-lowering effects. In our pilot study, treatment of bezafibrate or fenofibrate (100 mg⅐kg Ϫ1 ⅐day
Ϫ1
) in db/db mice for 8 wk did not significantly lower plasma levels of TG. In the next pilot study, treatment of bezafibrate (300 mg⅐kg Ϫ1 ⅐day
) or fenofibrate (300 mg⅐kg Ϫ1 ⅐day
) in db/db mice for 6 wk equipotently lowered plasma TG level (Vehi: 204 Ϯ 18 mg/dl; bezafibrate: 95 Ϯ 7, P Ͻ 0.01 mg/dl; fenofibrate: 85 Ϯ 5 mg/dl, P Ͻ 0.01 vs. vehicle-treated db/db mice). Notably, treatment of bezafibrate (300 mg⅐kg Ϫ1 ⅐day Ϫ1 ) significantly lowered plasma glucose level at 6 wk with an equipotency to rosiglitazone (Vehi: 473 Ϯ 24 mg/dl; bezafibrate: 216 Ϯ 40 mg/dl, P Ͻ 0.01; fenofibrate: 408 Ϯ 30 mg/dl, P ϭ 0.10; rosiglitazone: 197 Ϯ 23 mg/dl, P Ͻ 0.01 vs. vehicle-treated db/db mice). In the present study, we evaluated antidiabetic properties of bezafibrate and fenofibrate with the dose showing equipotent TG-lowering profile. In this context, TG-lowering profile in bezafibrate and fenofibrate in the present study indicates that the doses of drugs used were appropriate for assessing antidiabetic effects. Because we focused our special attention on PPAR␥ agonistic properties of bezafibrate, fenofibrate was employed as a "selective" PPAR␣ agonist. Therefore, we evaluated two doses (100 or 300 mg⅐kg Ϫ1 ⅐day Ϫ1 ) of bezafibrate and a single dose (300 mg⅐kg Ϫ1 ⅐day Ϫ1 ) of fenofibrate. Our results raise a couple of possibilities responsible for metabolically beneficial effects of bezafibrate. Decline of adiponectin levels is known (17, 33, 50) to associate with insulin resistance, hepatic fibrosis, and atherosclerosis in humans and rodents. In accordance with previous reports (10), plasma levels of adiponectin in db/db mice were significantly lower than those in vehicle-treated lean littermates (Fig. 1) . Notably, bezafibrate significantly increased plasma adiponectin levels in db/db mice, whereas fenofibrate did not provoke such effects. More importantly, we demonstrated for the first time that bezafibrate pronouncedly augmented the expression and secretion of adiponectin in 3T3-L1 differentiated adipocytes (Fig.  5) . Activation of PPAR␥ is known to increase plasma adiponectin levels in humans and rodents (27, 52) . First, the present study confirmed that pioglitazone and rosiglitazone increased plasma adiponectin levels in db/db mice (Fig. 1D) , Fig. 3 . 11␤-hydroxysteroid dehydrogenase type 1 (11␤-HSD1) mRNA levels in insulin target tissues of db/db mice treated with BF (100 or 300
), or vehicle and vehicle-treated lean mice (n ϭ 8 -10 in each). Each column shows 11␤-HSD1 mRNA levels in liver, triceps surae muscle (skeletal muscle; A), mesenteric fat, and subcutaneous fat (B) at 8 wk after the treatments were initiated. Each column represents %11␤-HSD1 mRNA levels compared with vehicle-treated db/db mice (defined as 100%). Data are presented as means Ϯ SE. *P Ͻ 0.05; **P Ͻ 0.01 vs. vehicle-treated db/db mice; ##P Ͻ 0.01 vs. vehicle-treated db/db mice. and rosiglitazone induced adiponectin expression and secretion in 3T3-L1 differentiated adipocytes (Fig. 5 ). To date, there has been only one report (31) that bezafibrate significantly increased plasma adiponectin levels in obese-diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Moreover, there were some reports (20, 21) showing that fenofibrate increased circulating adiponectin levels in humans. On the other hand, there was only one report (6) that fenofibrate increased mRNA levels of adiponectin in fat depots but did not increase serum levels in OLETF rats. A recent report (44) showed that WY-14,643, a selective PPAR␣ agonist, did not increase serum adiponectin levels in obese-diabetic KKA y mice. Collectively, the mechanistic link between PPAR␣ activation and elevation of circulating adiponectin still remains unclear. In the present study, fenofibrate and WY-14,643 did not change adiponectin secretion in 3T3-L1 adipocytes, suggesting that PPAR␣ activation by fenofibrate and WY-14,643 does not exert direct effects on adiponectin secretion. On the other hand, our data support the notion that bezafibrate directly influences adiponectin secretion in 3T3-L1 adipocytes. In contrast, several previous works (20, 21) have suggested that fenofibrate indirectly increased circulating adiponectin, presumably as a reflection of systemic improvement of fuel homeostasis. Our data suggest that bezafibrate-induced increase in plasma adiponectin levels is independent of PPAR␣ activation. Thus, it is likely that a significant increase in adiponectin level induced by bezafibrate may be attributable to its PPAR␥ agonistic activity (48) and thus contribute, at least partly, to the improvement of glucose metabolism in db/db mice. Future investigations to see whether bezafibrate could increase circulating adiponectin level in humans will be of great interest.
A previous report (19) demonstrated that fenofibrate significantly reduced plasma leptin levels in OLETF rats. In the present study, bezafibrate and fenofibrate did not significantly change plasma leptin levels. In contrast, consistent with previous reports (34, 37, 51), pioglitazone decreased plasma leptin . E: each column shows 11␤-HSD1 oxoreductase activity (n ϭ 3). Data are presented as means Ϯ SE. *P Ͻ 0.05; **P Ͻ 0.01 vs. nontransfected control. levels, presumably via PPAR␥ activation in adipocytes (Fig.  1C ). Taken together, a possible mechanistic link between PPAR␣ activation and leptin regulation remains obscure. There were a couple of studies (6, 19) showing that fenofibrate decreased body weight, as well as adipose tissue weight, in OLETF rats. In the present study, both bezafibrate and fenofibrate treatments tended to increase body weight and mesenteric fat weight (Table 2) . Because body weight increase was almost parallel to the increment in liver weight (Table 2) , it is likely that weight gain in both groups was largely attributable to liver hypertrophy caused by PPAR␣ activation.
Notably, with an equipotency to pioglitazone, bezafibrate markedly lowered the expression level of 11␤-HSD1 in mesenteric fat (Fig. 3B) . With a sharp contrast, fenofibrate did not change the expression of 11␤-HSD1. Importantly, bezafibrate markedly lowered the expression and enzyme activity of 11␤-HSD1 in 3T3-L1 differentiated adipocytes, equipotent to rosiglitazone and pioglitazone (Fig. 4) . To our knowledge, this is the first demonstration that bezafibrate potently reduces mRNA expression and enzyme activity of 11␤-HSD1 in cultured adipocytes. Our data clearly demonstrated that a knockdown of 11␤-HSD1 by transfection of siRNA duplex significantly reduced mRNA expression and enzyme activity of 11␤-HSD1 in 3T3-L1 differentiated adipocytes (Fig. 4, D and E) , confirming that 11␤-HSD1 acts as a distinct oxoreductase and activates glucocorticoid from inactive form. This result also validates the enzyme activity assays in the present study. It has been reported (4) that PPAR␥ agonists suppressed the expression levels of 11␤-HSD1 mRNA exclusively in adipocytes. In accordance with this notion, in the present study, pioglitazone markedly suppressed the 11␤-HSD1 mRNA in mesenteric and subcutaneous fat depots. Taken together, it is reasonable to speculate that bezafibrate suppresses 11␤-HSD1 in fat depots via its agonistic property for PPAR␥, thereby contributing, at least partly, to metabolically beneficial effects by bezafibrate.
It is important to note that the treatment of bezafibrate did not change circulating corticosterone levels in db/db mice in the present study. This indicates that, via the regulation of 11␤-HSD1, bezafibrate modifies intracellular glucocorticoid metabolism in a tissue-or cell-specific manner but does not affect systemic glucocorticoid homeostasis. The present study demonstrated that bezafibrate, fenofibrate, and pioglitazone significantly decreased 11␤-HSD1 mRNA levels in liver (Fig. 3A) . These effects may also explain unidentified, metabolically beneficial properties of fibrates (13, 25) , because transgenic mice overexpressing 11␤-HSD1 exclusively in liver exemplify fatty liver, glucose intolerance, dyslipidemia, and severe hypertension (36) . In this context, the potential pathophysiological role of 11␤-HSD1 in liver must await further investigation.
Bezafibrate has been characterized as a PPAR(␣, -␥, and -␦) pan-agonist in vitro (9, 48) . It was reported (24, 40, 42 ) that GW501516, known as a PPAR␦ agonist, exerts beneficial effects on insulin resistance. Thus, the activation of PPAR␦ by bezafibrate may also contribute to its metabolically beneficial effects. Although physiological relevance and an entire picture of the mechanism whereby bezafibrate ameliorates fuel dyshomeostasis in humans must await further investigation, our results presented here provide novel evidence that bezafibrate directly regulates 11␤-HSD1 and adiponectin in murine adipocytes. Further investigations on other rodent models and human clinics should validate its accuracy and may open a fresh avenue for therapeutic strategies that might target convergence of multiple risk factors. 
